• Product nameAnti-TGF beta antibody
    See all TGF beta primary antibodies
  • Description
    Rabbit polyclonal to TGF beta
  • Tested applicationsSuitable for: Indirect ELISA, Neutralising, WBmore details
  • Species reactivity
    Reacts with: Human, Pig
    Predicted to work with: Amphibians
  • Immunogen

    Recombinant full length proteins (Human, Pig, and Amphibian). A mixture of purified recombinant, human TGF-beta1, porcine TGF-beta 1.2, porcine TGF-beta 2 and recombinant, amphibian TGF-beta5



Our Abpromise guarantee covers the use of ab50716 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Indirect ELISA Use a concentration of 1 µg/ml.
Neutralising Use at an assay dependent dilution. The ND50 of the antibody is defined as the concentration of antibody resulting in a one-half maximal inhibition of bioactivity of recombinant, human TGF-b1 when the cytokine is present at a concentration just high enough to elicit a maximum response.
WB Use a concentration of 2 µg/ml. Predicted molecular weight: 44 kDa.


  • FunctionMultifunctional protein that controls proliferation, differentiation and other functions in many cell types. Many cells synthesize TGFB1 and have specific receptors for it. It positively and negatively regulates many other growth factors. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts.
  • Tissue specificityHighly expressed in bone. Abundantly expressed in articular cartilage and chondrocytes and is increased in osteoarthritis (OA). Co-localizes with ASPN in chondrocytes within OA lesions of articular cartilage.
  • Involvement in diseaseDefects in TGFB1 are the cause of Camurati-Engelmann disease (CE) [MIM:131300]; also known as progressive diaphyseal dysplasia 1 (DPD1). CE is an autosomal dominant disorder characterized by hyperostosis and sclerosis of the diaphyses of long bones. The disease typically presents in early childhood with pain, muscular weakness and waddling gait, and in some cases other features such as exophthalmos, facial paralysis, hearing difficulties and loss of vision.
  • Sequence similaritiesBelongs to the TGF-beta family.
  • Post-translational
    The precursor is cleaved into mature TGF-beta-1 and LAP, which remains non-covalently linked to mature TGF-beta-1 rendering it inactive.
  • Cellular localizationSecreted > extracellular space > extracellular matrix.
  • Information by UniProt
  • Database links
  • Alternative names
    • ARVD antibody
    • BSC 1 cell growth inhibitor antibody
    • CED antibody
    • Cetermin antibody
    • DPD1 antibody
    • G TSF antibody
    • Glioblastoma derived T cell suppressor factor antibody
    • LAP antibody
    • Latency-associated peptide antibody
    • Polyergin antibody
    • TGF beta 1 protein antibody
    • TGF beta 3 antibody
    • TGF beta1 antibody
    • TGF beta2 antibody
    • TGF beta3 antibody
    • TGF-beta-1 antibody
    • TGFB antibody
    • tgfb1 antibody
    • TGFB1_HUMAN antibody
    • TGFB2 antibody
    • TGFB3 antibody
    • TGFbeta antibody
    • Transforming growth factor antibody
    • Transforming growth factor beta 1 antibody
    • Transforming growth factor beta 2 antibody
    • Transforming growth factor beta 3 antibody
    see all

References for Anti-TGF beta antibody (ab50716)

ab50716 has not yet been referenced specifically in any publications.

Product Wall

Thank you for contacting us with your question and for your patience while I have been in touch with the lab about your enquiry.

I apologize for the confusion regarding the "alternative names" for our TGF-B antibodies. We would not ...

Read More

Thank you for your enquiry. As you can see on the datasheet of ab50716, this is a neutralising antibody and so is definitely binding to the active form of TGF in ELISA. Unfortunately we have no definite information availanle regarding binding of the an...

Read More